CloudMD Software & Services Inc.

Good afternoon and welcome to the CloudMD Q3 2021 earnings conference call and webinar. My name is Valerie and I'll be a conference facilitator today. As a reminder, this conference call is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer period. The company invites its covering analyst to ask questions during the conference call by pressing star then the number one on your telephone keypad. If a covering analyst would like you to draw their question, please press the pound key. Thank you. It is now my pleasure to turn the call over to Julia Becker, Vice President, Investor Relations, for the opening remarks.

Thank you, Valerie, and good afternoon, everyone. Thank you for joining us today, November 29, 2021, for our third quarter earnings conference call and webinar. We'll start the call off with our CEO, Dr. Issam Hamza, followed by our President, Karen Adams, and our Chief Financial Officer, Daniel Lee, who will provide a recap of the company's third quarter 2021 financial results before opening up for a question and answer period from our covering analysts. A friendly reminder that today's discussions contain certain forward-looking information, which involve inherent risks and uncertainties and other factors that could cause actual results to differ materially from management's current expectations. Forward-looking information should not be interpreted as assurances of future performance or results. The risks related to forward-looking information are described in the company's most recent AIF and in the management discussion and analysis for Q3 2021, which are both available on CEEDAR. We encourage you to review our public disclosure in the context of all forward-looking information that you may hear today during this earnings conference call. Investors are cautioned not to place undue reliance on such forward-looking information and that such information is considered reasonable based on information available to management as of today. However, the company disclaims any intention or obligation to update or review any forward-looking information as a result of new information, future events, or for any other reason except to the extent required by law. With that, it is my pleasure to turn the call over to Dr. Issam Hamza, CEO of CloudMD.

Thank you, Julia. Good afternoon, and thank you for joining us for our third quarter 2021 earnings call. We are delighted to share our financial results representing the first full quarter with all of our previously reported acquisitions closed and consolidated. This is the first quarter where our investors can start to see the full impact of CloudMD's strategy. Through the execution of the strategy, we generated $39.2 million in revenue, representing over 1,000% year-over-year growth and positive adjusted EBITDA. demonstrating the operating leverage inherent in our business model. We've increased our adjusted EBITDA margin for six consecutive quarters as we've successfully executed on our integration playbook to generate significant synergies. Let me now talk briefly about the underlying philosophy that guides us and has led to those outstanding results. CloudMD was born out of the frustration of dealing with the inefficiencies and ineffectiveness of the traditionally broken healthcare system. Many of you are here because, like us, you recognize the failings of that system. For example, inefficient use of resources, siloed care, outdated technology, employers or payers dealing with rising costs despite worsening outcomes, and doctors and nurses that are overwhelmed and exhausted. Our team of dedicated medical professionals understand the historical shortcomings and the different pain points of those various stakeholders, As a result, we have created a health tech company leveraging proprietary patented technology, which is focused on an integrated outcomes-based approach to healthcare delivery, and which improves efficiencies, provides better access of care, and better health outcomes. We know that payers and providers prefer integrated end-to-end solutions because it simplifies partnerships, improves return on healthcare spend, and leads to better individual health outcomes. we've carefully built a leading integrated solution through a combination of strategic acquisitions and purposeful technology innovation. All these targeted acquisitions fill an essential part of our healthcare ecosystem in either our enterprise health solutions or digital health solutions product roadmap. Most of these were not for sale on the market and were founder-led companies that, like you, align with the CloudMD vision. We are uniquely positioned to deliver a comprehensive integrated health offering based on our patented real-time intervention platform, or RTIP, which supports data interoperability, cybersecurity, and the ability to merge separate applications into a single platform. It is the backbone of our comprehensive platform and allows us to integrate various health capabilities, such as care navigation, physical health, mental health, virtual care, and health education, to name a few. This integration allows us to navigate an individual's unique health journey within one connected platform and provide outcome data back to the stakeholders. RTEP makes it much easier and more effective for us to continue adding new capabilities onto the platform, share data in real time, and operate as an end-to-end solution. It also allows us to scale rapidly and enter new geographical locations by plugging provider networks into our backend. On the call today, I'm going to have Karen talk about three key focus areas that are driving growth and shareholder value. One, we are driving synergies and integrating capabilities to improve growth and profitability. Two, through our enterprise health solutions division, we are delivering an excellent end user experience for all stakeholders, which is driving successful customer acquisition. Three, Through our Digital Health Solutions Division, we have developed proprietary technology that enables engagement of individuals in supporting health issues, while at the same time empowering regulated health professionals' productivity. I'll now pass it over to Karen to review in detail how we will execute against each one of these focus points. Karen?